Back to Stakeholders
Categories

2 domains / 4 areas / 2 specializations

Care Delivery & Psychedelic Facilitation
Care Delivery & Psychedelic Facilitation
Clinical Care Delivery OrganizationsHealth Systems & Hospitals
Research, Drug Development & Manufacturing
Academic & Non-Profit ResearchIndependent Academic Research Groups
Research, Drug Development & Manufacturing

Mayo Clinic

Data updated

United States
8 Trials1 Paper

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

Academic Research

1 papers

Published Papers

1

Trial Involvement

8

Distinct Focus Topics

0

Latest Publication

Feb 7, 2026

Recent Papers

Clinical Care Delivery Snapshot

Health Systems & Hospitals

Provider Model

Health System / Hospital Program

Organization Status

Unknown

Psychedelic Services

Unknown

Service Coverage

Global

Service Profile

Care Settings

Hospital Outpatient

Payer Models

Unknown

Non-Psychedelic Service Mix

Unknown

Visit Provider

Care Delivery Notes

Backfilled profile for existing L2 clinical care delivery stakeholder.

Sources

Official website

https://www.mayoclinic.org

Quick Facts

Type
Other
HQ
United States
Website
Visit

Sponsored Trials

7
RecruitingII

Intravenous Ketamine for Treatment-Resistant Depression (G2K)

Start Date
Compounds
Ketamine, Placebo
RecruitingII

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Start Date
Compounds
Ketamine, Placebo
Active not recruitingI

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission

Start Date
Compounds
Ketamine
CompletedIV

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

Start Date
Compounds
Ketamine
CompletedII

Ketamine for Depression and Suicide Risk

Start Date
Compounds
Ketamine
TerminatedII

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Start Date
Compounds
Ketamine, Placebo
CompletedNA

Ketamine Anesthesia in Electroconvulsive Therapy

Start Date
Compounds
Ketamine, Placebo

Collaborated Trials

1
CompletedII

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

Start Date
Compounds
Ketamine, Placebo

Research Papers

1
Open Accessmeta

Oral Ketamine for Chronic Pain: Towards an Evidence-Based Dosing Regimen

This systematic review (s=27) of oral ketamine for chronic cancer and non-cancer pain found that mean pain scores fell from 7.72/10 to 3.2/10 over 30 to 90 days, though only 5 studies had sufficient dosing consistency for quantitative analysis, with 35 mg/70kg three times daily identified as an effective regimen with an acceptable safety profile.

Published
Journal
Journal of Pain Research
Authors
Winegarden, J., Brose, A., Storm, A., Mortensen, A., Carr, D.